Voglow 0.3 GM 2 Tablet SR
By Voglow GM
Rx
15 Tablet SR in a Strip

Composition
Glimepiride(2mg) + Metformin(500mg) + Voglibose(0.3mg)

Manufacturer - Primus Remedies Pvt Ltd
Primus Remedies Pvt Ltd, C-16, Ankur Cooperative Society, Thakurli Estate, Dombivili, Mumbai-421202.

Expires on or after
April, 2027

liver
When using Voglow 0.3 GM 2 Tablet SR, it is important to be cautious if you have liver disease. Patients with liver issues may require a dose adjustment when taking this medication, so it's crucial to consult your doctor before starting treatment. Typically, Voglow 0.3 GM 2 Tablet SR is initiated at a low dose for individuals with mild to moderate liver disease. However, it is not advised for use in patients with severe liver disease. Be sure to seek guidance from your healthcare provider to ensure the safe and appropriate use of Voglow 0.3 GM 2 Tablet SR.

kidney
Voglow 0.3 GM 2 Tablet SR may not be safe for patients with kidney disease. It is advised to avoid using this medication if you have kidney issues. Please consult your doctor before taking Provog GM Tablet SR, especially if you have severe kidney disease.

alcohol
It is not safe to drink alcohol while taking Voglow 0.3 GM 2 Tablet SR.

driving
It is important to note that your driving ability may be impacted if you experience low or high blood sugar levels while taking Voglow 0.3 GM 2 Tablet SR. It is advisable to avoid driving in such situations.

pregnancy
Voglow 0.3 GM 2 Tablet SR may not be safe to use during pregnancy. Animal studies indicate potential harm to the baby's development. Your doctor will assess the risks versus benefits before prescribing. Consulting your doctor is advised.

breastfeeding
Voglow 0.3 GM 2 Tablet SR is likely unsafe during breastfeeding as it may pass into breastmilk and harm the baby based on limited data.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹226
Inclusive of all taxes
Content verified by

Dr. Upasana Bhatia
MBBS - General Medicine
Last update on 01-Oct-2024